Mode
Text Size
Log in / Sign up

Hepatitis A

Part of Hepatitis

10 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hepatitis A

22 trials tracked for Hepatitis A: 20 in phase 3 or 4.

22Trials tracked
20Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 9 Phase 3 11 Phase 2 1 Other / NA 1
  1. Phase 4 Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc Completed
  2. Phase 4 Long-term Persistence Study in Healthy Adults Previously Vaccinated With Twinrix Adult Completed
  3. Phase 4 Evaluation of Antibody Persistence & Immune Memory in Subjects Vaccinated During Adolescence With Twinrix™ Completed
  4. Phase 4 Antibody Persistence & Immune Memory in Healthy Adults Previously Vaccinated With Twinrix Adult Completed
  5. Phase 4 Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Injected According to a 0, 12-month Schedule Completed
  6. Phase 4 Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) Completed
Show 16 more trials
  1. Phase 4 A Study to Evaluate the Safety and Immunogenicity of the Hepatitis A Virus Vaccine HAVpur in Healthy Young Children Completed
  2. Phase 4 Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination Completed
  3. Phase 4 Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine, Injected According to 0, 6-month Schedule Completed
  4. Phase 3 Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age Completed
  5. Phase 3 Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months Completed
  6. Phase 3 Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Month Schedule Completed
  7. Phase 3 Long-term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Mth Schedule in Healthy Adults Completed
  8. Phase 3 A Study of 2 Doses of VAQTA™ in Healthy Children 12 to 23 Months of Age (V251-069) Completed
  9. Phase 3 Long-Term Follow-Up Studies at Year 6, 7, 8, 9, 10: 2 Formulations of Combined Hepatitis A/B Vaccine Compared in Subjects Aged 12-15 Years Completed
  10. Phase 3 Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children Completed
  11. Phase 3 Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine Completed
  12. Phase 3 Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines Completed
  13. Phase 3 Long Term Follow-up Study at Years 2, 3, 4 and 5 Where 2 Dosing Schedules of the Combined Hepatitis A and B Vaccine Were Compared Completed
  14. Phase 3 Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,6 Month Schedule Completed
  15. Phase 2 Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children Completed
  16. N/A A Randomized Trial of Vaccine Adherence in Young Injection Drug Users Completed

Showing the 22 most-cited and recently-updated of 22 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Hepatitis

Related studies from across the Hepatitis family.

Eight-Week Sofosbuvir-Velpatasvir Matches Twelve-Week Course in Non-Cirrhotic Hepatitis C
Gastroenterology RCT
Eight-Week Sofosbuvir-Velpatasvir Matches Twelve-Week Course in Non-Cirrhotic Hepatitis C Trial shows 8-week treatment works for Hepatitis C
In 880 treatment-naive adults with non-cirrhotic hepatitis C, 8 weeks of sofosbuvir-velpatasvir achieved SVR12 rates similar to the standard…
A shorter 8-week course of sofosbuvir and velpatasvir showed similar success rates to the standard 12-week treatment for Hepatitis C patient…
HBeAg positivity and high HBV DNA levels increase postpartum ALT elevation risk in chronic hepatitis B
Primary Care & Family Medicine Meta-analysis
HBeAg positivity and high HBV DNA levels increase postpartum ALT elevation risk in chronic hepatitis B Risk Factors for Liver Inflammation in Mothers with Hepatitis B
This meta-analysis of cohort studies identifies key risk factors for postpartum alanine aminotransferase (ALT) elevation in women with chron…
Specific factors like HBeAg positivity and high viral DNA levels can increase the risk of liver inflammation in women with chronic hepatitis…
HBsAg prevalence 7.0% in dialysis patients, with low HBV-DNA and suboptimal vaccination
Infectious Disease Meta-analysis
HBsAg prevalence 7.0% in dialysis patients, with low HBV-DNA and suboptimal vaccination Hepatitis B infection rates among patients on dialysis
This meta-analysis of 79 articles estimates hepatitis B burden in dialysis patients globally. Pooled HBsAg prevalence was 7.0% (95% CI 6.1-8…
New data shows that about 7% of patients on dialysis have Hepatitis B, highlighting the need for safer procedures and better vaccination rat…
Community health workers support infectious disease management and PrEP navigation in agricultural communities
Neurology Sys. Review
Community health workers support infectious disease management and PrEP navigation in agricultural communities Community health workers help farm workers manage infectious diseases
This mini-review examines the role of community health workers (CHWs) in managing infectious diseases among California agricultural workers.…
Community health workers can help farm workers manage serious infections like HIV, tuberculosis, and hepatitis through direct outreach and n…
Hepatic macrophage metabolic reprogramming and bidirectional signaling dictate the balance between liver injury and regeneration
Gastroenterology Sys. Review
Hepatic macrophage metabolic reprogramming and bidirectional signaling dictate the balance between liver injury and regeneration New research identifies how liver cells communicate during chronic disease
This systematic review synthesizes the role of hepatic macrophages in metabolic dysfunction-associated steatotic liver disease, alcohol-asso…
New research reveals how specific immune cells in the liver switch between causing inflammation and repairing tissue damage.
Tonsillar metastasis in hepatocellular carcinoma patients may present as undifferentiated carcinoma with specific IHC markers
Oncology Sys. Review
Tonsillar metastasis in hepatocellular carcinoma patients may present as undifferentiated carcinoma with specific IHC markers Lenvatinib and Chemoembolization Treatment Linked to Liver Cancer Metastasis
This case report and literature review describes a single patient with hepatocellular carcinoma and chronic hepatitis B presenting with a to…
A rare case of liver cancer spreading to the tonsils highlights the need for careful monitoring of head and neck symptoms in patients with l…
Global HBsAg prevalence 3.2% in nurses, with 5.6% in Africa and 3.6% in LMICs
Gastroenterology Meta-analysis
Global HBsAg prevalence 3.2% in nurses, with 5.6% in Africa and 3.6% in LMICs Nurses Face Higher Hepatitis B Risk in Poorer Countries
This meta-analysis estimates global hepatitis B surface antigen (HBsAg) prevalence among hospital-based nurses at 3.2% (95% CI 2.3-4.4), wit…
A global analysis finds 3.2% of hospital nurses carry hepatitis B, with rates four times higher in poorer countries.
Host non-coding RNAs orchestrate antiviral defense and are targeted by viral counter-defense strategies
Diabetes & Endocrinology Sys. Review
Host non-coding RNAs orchestrate antiviral defense and are targeted by viral counter-defense strategies Host molecules may help the body fight off common viruses
This systematic review examines how host non-coding RNAs, including miRNAs, lncRNAs, circRNAs, and vtRNAs, modulate antiviral responses agai…
Your body uses special molecules called non-coding RNAs to fight off viruses like flu, Zika, and COVID-19 by blocking their growth.
Incarceration acts as a structural determinant of health with higher rates of chronic and infectious diseases
Primary Care & Family Medicine Sys. Review
Incarceration acts as a structural determinant of health with higher rates of chronic and infectious diseases Incarceration Linked to Higher Rates of Mental Illness and HIV
This narrative review of 167 articles examines the health status and care utilization of incarcerated adults in Canada. It finds significant…
People in correctional centers face higher rates of mental illness and chronic diseases compared to those living in the community.
Peg-interferon add-on to nucleoside analogues achieves HBsAg loss in 8.6% of patients
Infectious Disease Meta-analysis
Peg-interferon add-on to nucleoside analogues achieves HBsAg loss in 8.6% of patients Adding peg-interferon to standard treatment helps some hepatitis B patients
This meta-analysis of 581 patients with chronic hepatitis B evaluates peg-interferon add-on to nucleoside analogue therapy. The analysis fou…
Adding peg-interferon to standard nucleoside therapy can help some patients with chronic hepatitis B achieve a key milestone in their treatm…
Viral hepatitis infections pose significantly higher risk for liver cancer than smoking-related lung cancer
Oncology Meta-analysis
Viral hepatitis infections pose significantly higher risk for liver cancer than smoking-related lung cancer Comparing the risks of liver cancer from hepatitis versus lung cancer from smoking
This meta-analysis of 86,097,714 participants analyzed the relative risks of liver cancer from various exposures compared to lung cancer fro…
New data shows that certain hepatitis viruses pose a much higher risk for liver cancer than smoking does for lung cancer.
Major HCV genotypes G1, G2, and G3 account for 98.02% of infections in FSU regions
Gastroenterology Meta-analysis
Major HCV genotypes G1, G2, and G3 account for 98.02% of infections in FSU regions Analysis Reveals Hepatitis C Genotype Patterns in Former Soviet Union
This scoping review and genotype meta-analysis analyzes HCV genotype distribution and resistance-associated substitutions (RAS) in the Forme…
New data maps the distribution of Hepatitis C genotypes and resistance mutations across the Former Soviet Union to help improve regional mon…

Questions about Hepatitis A

What details are available about the recent Hepatitis A outbreak in the United States?

Recent data shows a sharp rise in Hepatitis A cases across the U.S., with outbreaks linked to contaminated food, water, and specific geographic areas like Los Angeles County.

Full answer →
What role did molecular testing play in the Los Angeles County Hepatitis A outbreak?

Molecular testing identified the specific strain of the virus in Los Angeles County, confirming the outbreak was caused by a single source and allowing officials to trace the spread to wastewater contamination.

Full answer →
What are the new Hepatitis A immunization recommendations for the United States?

New recommendations focus on vaccinating adults at risk, including those who use drugs, are homeless, or have chronic liver disease, due to a major shift in how the virus spreads.

Full answer →